Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells
Open accessThe DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Abstract
The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Molecular pathways and cellular interactions involved in HSC activation and deactivation. Activated HSCs are the main effector cells during hepatic fibrosis. In the healthy liver, they metabolize and store retinoids. Upon activation by fibrogenic stimuli, quiescent HSCs transdifferentiate into myofibroblasts, lose their vitamin A, upregulate α-smooth muscle actin (αSMA), and produce collagen I. Various factors, including immune cell-derived fibrogenic molecules, growth factors, and lipopolysaccharide, as well as profibrotic lipid mediators such as lysophosphatidylinositol and lysophosphatidic acid, induce HSC activation in the course of chronic liver disease. TGF-β is the most HSC potent activator, which is produced by infiltrating lymphocytes and monocytes, Kupffer cells (KCs), and damaged hepatocytes. IL-17, produced by neutrophils and Th17 cells, sensitizes HSCs to TGF-β by upregulating TGF-β receptor II (TGF-βRII). In addition, platelet-derived growth factor (PDGF), which is produced by endothelial cells and macrophages, further promotes HSC activation. During fibrosis resolution, HSCs either die or revert to an inactive state by upregulating transcription factors such as peroxisome proliferator-activated receptor-γ (PPARγ), GATA-binding factor 4 (GATA4), GATA6, and transcription factor 21 (TCF21). NK and CD8+ T cells can eliminate activated HSCs by inducing apoptosis (Further abbreviations: GM-CSF, granulocyte/macrophage colony-stimulating factor; HH, hedgehog ligands; IHH, Indian Hedgehog; LPA, lysophosphatidic acid; LPI, lysophosphatidylinositol; LPS, lipopolysaccharide; miRNA, microRNA; MSR1, macrophage scavenger receptor 1; NF-κB, nuclear factor κ-light chain-enhancer of activated B cells; OPN, osteopontin; oxLDL, oxidized low-density lipoprotein; ROS, reactive oxygen species; S1P, sphingosine-1-phosphate; SHH, sonic hedgehog; TLR4, Toll-like receptor 4). Modified from reference [5].](https://figures.cochat.ai/paper-figures/ba56d748dfcc4395a6907c0c93306af8/liver-fibrosis-from-basic-science-towards-clinical-progress-focusing-on-the-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A pivotal element in acute and chronic liver damage is hepatic stellate cells (HSCs) activation. In response to hepatocyte injury, HSCs transition into activated myofibroblasts, overproducing extracellular matrix components and driving fibrosis (Akkız H, 2024).”
From A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis (2026) · cites this paper as Akkız H, 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neutrophil Extracellular Traps Kill Bacteria
Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D. S., Weinrauch, Y., & Zychlinsky, A. (2004) · Science · doi:10.1126/science.1092385 · Cited by 10,268 · cited 2×
“Neutrophils are critical first responders of the innate immune system, and they can contribute to hepatic inflammation by producing proinflammatory cytokines and neutrophil extracellular traps (NETs), activating KCs, and recruiting additional types of immune cells [60–62].”
BackgroundMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · cited 1×
“…factor, liver fibrosis reverts, going along with the decreased production of proinflammatory and profibrogenic cytokines, upregulated collagenolytic activity, the disappearance of fibrogenic cells, decreased ECM production, and, eventually, the dissolution of the fibrosis scar [1,2,4,5,13–17].”
BackgroundTGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380 · cited 3×
“Senescent HSCs are α -SMA-positive cells, but they neither proliferate nor produce collagen [2,5,10,11].”
BackgroundVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492 · cited 1×
“In contrast, successful antiviral treatment in patients with chronic viral hepatitis or with considerable lifestyle changes in NASH patients modulate the resolution of fibrosis [6–9].”
BackgroundInterleukin-17 Family Members and Inflammation
Kolls, J. K., & Lindén, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.018 · Cited by 2,372 · cited 1×
“ILCs, particularly ILC1s and ILC3s, are involved in liver fibrogenesis [82,83].”
BackgroundMolecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · cited 10×
“…accumulation of bone marrow-derived inflammatory immune cells, secretion of proinflammatory cytokines, production of TGF-β by profibrogenic macrophages, activation of collagen type I (COLIAI)-secreting hepatic myofibroblasts, excessive production of the ECM, and the formation of a fibrous scar [4].”
BackgroundInfluentialAlcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963 · cited 1×
“In mice, the elimination of neutrophils or the deletion of neutrophil-derived soluble molecules (IL-8, IL-18, IL-17, CCL3, CCl 4 , and CCL2) attenuates the development of hepatic fibrosis [63,64].”
BackgroundTLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942 · cited 1×
“Blocking TLR4 signaling in mice or reducing hepatic exposure to intestinal microorganisms improves liver fibrosis [81].”
BackgroundFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868 · cited 10×
“The combination of low extracellular pH with an increased lactic acid level promotes myofibroblast transformation through the activation of TGF-β 1 [1,144–146].”
BackgroundInfluential
Cited by
Tauil, R. B., Golono, P. T., de Lima, E. P., Goulart, R. D. Á., Guiguer, É. L., Bechara, M. D., Nicolau, C. C. T., Yanaguizawa, J. L., Fiorini, A. M. R., Méndez‐Sánchez, N., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17101354 · Cited by 85
Giangregorio, F., Mosconi, E., Debellis, M. G., Provini, S., Esposito, C., Garolfi, M., Oraka, S., KALOUDI, O., Mustafazade, G., Marín‐Baselga, R., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195880 · Cited by 79
“However, not all healthcare institutions have access to advanced imaging technologies like VCTE or MRE.”
BackgroundPuri, M., & Sonawane, S. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093988 · Cited by 41
“Furthermore, LSECs themselves become more susceptible to the effects of TGF-β , which contributes to their capillarization and loss of normal function [42].”
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 36
Present and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 35
“Conversely, hypomethylation of pro-fibrotic genes like TGF β 1 promotes sustained fibrogenic signaling, leading to continuous HSC activation and excessive ECM production [49–51].”
Immunomodulatory Significance of Mast Cell Exosomes (MC-EXOs) in Immune Response Coordination
Komi, D. E. A., Shafaghat, F., Alipoor, S. D., Kazemi, T., Atiakshin, D., Pyatilova, P., & Maurer, M. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09033-6 · Cited by 27
Li, Y., Jian, Y., Zhou, J., Zhang, M., Zhou, Y., Yang, G., Wang, H., & Mu, W. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118431 · Cited by 23
Liu, Q., Li, J., Li, X., Zhang, L., Yao, S., Wang, Y., Tuo, B., & Jin, H. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5429 · Cited by 24
“HScs in the normal liver are quiescent, nonprolif‑ erative, periportal, hepatic sinusoidal cells (70). during liver injury, HSCs are activated and transdifferentiate into myofi‑ broblasts with contractile and proliferative properties (16).”
BackgroundBeyond M1/M2: The role of reactive oxygen species in liver fibrosis and immune modulation
Lu, H., Huang, J., Wang, Y.-C., Casals, E., Casals, G., & Zeng, M. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103933 · Cited by 19
“If not effectively managed, fibrosis can advance to cirrhosis, characterized by extensive scarring and impaired liver function [13 – 15].”
Cui, X., Zhang, R., Li, P., Li, P., Liu, Y., Yu, X., Zhou, J., Wang, L., Tian, X., Li, H., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118910 · Cited by 20
Advances in intrahepatic and extrahepatic vascular dysregulations in cirrhotic portal hypertension
Li, Y., Zhu, B., Shi, K., Lu, Y., Zeng, X., Li, Y., Zhang, Q., Feng, Y., & Wang, X. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1515400 · Cited by 23
The role of matrix metalloproteinases in liver function and disease
Mitropoulou, G., Kompoura, V., Saffioti, F., & Mavroeidis, V. K. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl27127 · Cited by 14
Bai, J., Xie, N., Hou, Y., Li, C., Gao, P., Qi, L., Nie, X., Yan, J., Zeng, Y., Zhang, Y., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157540 · Cited by 19
Widowati, W., Sabrina, A. H. N., Sutendi, A. F., Zahiroh, F. H., Nurjamil, A. M., Wargasetia, T. L., Nainggolan, I. M., Azis, R., Rismani, E., & Vosough, M. (2026) · Journal of Immunology Research · doi:10.1155/jimr/2656395 · Cited by 18
Immune Checkpoints and the Immunology of Liver Fibrosis
Tsomidis, I., Voumvouraki, A., & Kouroumalis, E. (2025) · Livers · doi:10.3390/livers5010005 · Cited by 16
Losasso, M. R., Parussolo, M. L. C., Silva, A. O., Direito, R., Quesada, K. R., Detregiachi, C. R. P., Bechara, M. D., Méndez‐Sánchez, N., Abenavoli, L., Araújo, A. C., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104673 · Cited by 18
“This relationship thus contributes to oxidative stress, thereby creating a biological imbalance that results in initial cellular changes evolving into systemic manifestations [65–69].”
Functional mechanisms and potential therapeutic strategies for lactylation in liver diseases
Xu, R., Hao, Y., Liu, Y., Ji, B., Tian, W., & Zhang, W. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123395 · Cited by 16
Zhao, F., Niu, X., Song, G., Wang, L., Fu, Y., Li, S., Gu, X., Wang, Q., & Luo, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06880-x · Cited by 18
“Excessive activation of HSCs is considered as a central driver of liver fibrogenesis [5–7].”
Molecular insights into herbal medicines for the treatment of metabolic associated Steatohepatitis
Addissouky, T. A. (2025) · Discover Chemistry. · doi:10.1007/s44371-025-00212-0 · Cited by 14
Zhu, Z., Wang, S., Liu, X., Liu, N., Dong, D.-C., Qi, Y., Li, N., Wang, N., Tan, J. H., Jia, C., et al. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.124661 · Cited by 12
Nanogene editing drug delivery systems in the treatment of liver fibrosis
Wang, Q., Jia, S., Wang, Z., Chen, H., Jiang, X., Li, Y., & Ji, P. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1418786 · Cited by 13
Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review
Tavakoli, S., Salavatipour, M. S., Rahnama, M. A., Abdolahi, S., Hassanzadeh, A., Ghazvinian, Z., Verdi, J., Vousooghi, N., Manoochehrabadi, S., Chahardouli, B., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-03138-2 · Cited by 19
Liu, F., Sun, Y., Tai, D., Ren, Y., Chng, E., Wee, A., Bédossa, P., Huang, R., Wang, J., Wei, L., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14161837 · Cited by 8
“Therefore, there is an urgent need to develop more effective treatments to reverse liver fibrosis and prevent its progression to cirrhosis [4–6].”
BackgroundHuang, C., Liang, H., Liang, X., Liu, Y., Wang, J., Jiang, H., Kou, X., Chen, J., & Huang, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1567210 · Cited by 14
Amphiregulin: a potential therapeutic target for tissue fibrosis
Wang, M. H., Liu, J., Li, S., Zheng, M., Qu, R. Y., & Xiang, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.06.002 · Cited by 12
Zhang, Y., Dou, J., Dai, S., Xie, Y., Wang, H., Chen, Z., Zhuang, H., & Xu, S. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04526-9 · Cited by 9
Song, J., Ma, N., Aini, R., & Yang, Y. (2025) · American Journal of Translational Research · doi:10.62347/kevq8263 · Cited by 7
Advanced 3D In Vitro Liver Fibrosis Models: Spheroids, Organoids, and Liver-on-Chips
Lee, J. E., Lee, Y., & Yoon, J. (2025) · Biomimetics · doi:10.3390/biomimetics10100639 · Cited by 8
“As fibrosis advances, it may lead to cirrhosis, accompanied by architectural distortion and functional impairment of the liver [5,6].”
Kim, D. H., Ko, D., Chen, V. L., Porres, J. A., Alatorre, C. E., Nieto, L. M., Argueta, P. P., Kröner, P. T., Lukens, F. J., Kim, D., et al. (2025) · Liver International · doi:10.1111/liv.70490 · Cited by 9
“Interleukins like TNF-a and IL-6 help perpetuate hepatic damage and act synergistically with TGF-B to drive the process of fibrosis [26] in MASH cirrhosis, and it has been proposed that SGLT-2 inhibitors may inhibit these proinflammatory cytokines, reducing overall inflammation and fibrosis [27],…”
Sun, Y., Zhuang, Y., Cheng, K., Wei, Y., Li, M., Xuan, J., Zheng, S., Guo, M., & Zhang, Z. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157912 · Cited by 8
Mochida, T., Miyoshi, M., Kakinuma, S., Shimizu, T., Tsuchiya, J., Watakabe, K., Inada, K., Kaneko, S., Kawai‐Kitahata, F., Murakawa, M., et al. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102642 · Cited by 6
Chen, L. T. J., Chen, C., Chen, Q., Jiang, T., Zheng, L., Tang, R., & Wang, C. (2025) · Inflammation · doi:10.1007/s10753-025-02407-0 · Cited by 7
Vitamin A and its influence on tumour extracellular matrix
Xie, G., Cao, S., Wang, G., Zhang, X., Zhang, Y., Wu, H., Shen, S., Le, J., Li, K., & Huang, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-01751-9 · Cited by 7
“This, in turn, decreases the production of collagen and other ECM components, thereby improving the permeability of chemotherapy drugs in the tumour microenvironment [105].”
Sun, T., Wang, B., Li, X.-Y., Zhang, X., Lei, Y., Yu, S., & Li, N. (2025) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_634_24 · Cited by 6
JTCD attenuates HF by inhibiting activation of HSCs through PPARα-TFEB axis-mediated lipophagy
Shao, C., Lan, W., Ding, Y., Ye, L., Huang, J., Liang, X., He, Y., & Zhang, J. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156501 · Cited by 9
Li, S., Qi, S., Li, R., Yang, F., Niu, Z., Liu, W., Ma, S., & Xiao, Z. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1614341 · Cited by 5
Huang, P., Zhu, Y., Li, Z., Zeng, K., Qin, L., Hu, J., Zhang, T., Zhang, L., Liu, T., & Qin, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116007 · Cited by 6
Elbadawy, H. M., Almikhlafi, M. A., Alsubhi, M. H., Shokry, A. A., Fayed, H. M., Mohamed, B. M. S. A., Afifi, S. M., Esatbeyoglu, T., Korany, R. M. S., & Elbaset, M. A. (2025) · Oxidative Medicine and Cellular Longevity · doi:10.1155/omcl/7684652 · Cited by 5
Demyashkin, G. A., Алексеевич, П. М., Koryakin, S. N., Skovorodko, P., Shchekin, V. I., Yakimenko, V. A., Uruskhanova, Z., Ugurchieva, D. I., Pugacheva, E., Иванов, С. А., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12102195 · Cited by 7
“These activated cells further exacerbate liver damage by releasing pro-inflammatory cytokines, including TNF-α , IL-1, and IL-6, which amplify the inflammatory response [15,16].”
BackgroundImplications of liver fibrosis in clinical trials
Jahagirdar, V., Rama, K., Cabrera, D., Idalsoaga, F. J., Díaz, L. A., Arrese, M. A., & Arab, J. P. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102112 · Cited by 7
Fu, R., Zhang, F., Fu, J., Li, Y., Zhu, X., Ding, Q., & Zhu, Y. Z. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.163 · Cited by 7
Prasad, K., Bhattacharya, D., Shams, S. G. E., Izarraras, K., Hart, T., Mayfield, B., Blaszczyk, M. B., Zhou, Z., Pajvani, U. B., Friedman, S. L., et al. (2024) · Cells · doi:10.3390/cells13191651 · Cited by 7
“Activated HSCs acquire the characteristics of mesenchymal fibroblast cells and produce various extracellular matrix constituents, such as collagen, fibronectin, and α -smooth muscle actin ( α -SMA) [1,2].”
BackgroundLee, D. Y., Jung, K., Lee, J. H., Kang, H. J., Lee, J. Y., Kim, J., Ham, D., Cho, J., Eom, D., & Kang, K. S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177272 · Cited by 5
TNAP-induced CD47 membrane expression enhances TGF-β1 conversion in liver fibrosis
Gao, L., Peng, F., Peng, Q., Zhang, H., Chi, H., Deng, L., Liang, X., Sun, M., Ma, W., Yang, C., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000781 · Cited by 5
“…transformation, acquiring a fibroblast-like shape and expressing alpha-smooth muscle actin ( α -SMA), thereby becoming the primary source of MFBs. [4] TGF-β 1 plays a critical role in liver fibrosis by promoting the differentiation of HSCs. [5] However, targeting TGF-β 1 signaling for…”
Chen, Q., Li, C., Ding, W., & Kong, D. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503273 · Cited by 7
Vitisin A inhibits liver fibrosis by promoting Nrf2/HO-1 pathway and inhibiting Cuproptosis
Ding, S., Hu, D., Pan, Y. F., Wang, J., & Wang, L. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-27836-7 · Cited by 4
Ma, X., Chen, D., Zhao, M., & Hu, H. (2026) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70046 · Cited by 6
Human Liver MSCs Retain Their Basic Cellular Properties in Chronically Inflamed Liver Tissue
Kim, Y. S., Lupatov, A. Y., Burunova, V. V., Bagmet, N. N., Chardarov, N. K., Malov, S. L., Kholodenko, R. V., Шатверян, Г. А., Manukyan, G. V., Yarygin, K. N., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413374 · Cited by 4
Šarić, J. P., Lulić, D., Rogić, D., Jadrijević, S., Mikulić, D., Kanižaj, T. F., Prpic, N., Bozic, L. K., Adamovic, I., Kocman, I. B., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199584 · Cited by 5
“Sustained stimulation gradually reprograms stellate cells into a fibrogenic state characterized by enhanced collagen synthesis and reduced matrix degradation, supported by contractile and proliferative changes that consolidate their myofibroblastic phenotype [23–27].”
Ma, L., Weng, W., Chen, J., Wu, H., Liang, J., & Lu, F. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02228-y · Cited by 3
“Moreover, despite extensive experimental studies of antifibrotic drugs, effective therapeutic approaches are still lacking clinically [3].”
Hong, T. H., Park, J. H., Hong, H., Choi, H. J., Kim, O., & Kim, S. (2025) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e294 · Cited by 6
Prêle, C. M., Braack, K. J., Atlas, M. D., Kuthubutheen, J., Miles, T., Mulders, W. H. A. M., & Mutsaers, S. E. (2025) · Cells · doi:10.3390/cells14231924 · Cited by 4
“Within the liver, hepatic stellate cells are the predominant collagen secreting cells activated by immune cells and pro-fibrogenic mediators to differentiate into myofibroblasts [95].”
Fu, L., Shang, J., Zheng, L., Zhang, X., Cui, A., Dou, X., Li, Y., & Liu, J. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04243-5 · Cited by 3
Yang, S., & Cheng, A. (2026) · BMC Medical Genomics · doi:10.1186/s12920-025-02278-2 · Cited by 3
“Persistent inflammation induces hepatocyte injury and demise, thereby activating hepatic stellate cells (HSCs) and prompting their transformation into profibrotic entities, which ultimately culminates in liver fibrosis and cirrhosis [14].”
Cai, Y., Nie, T., Luo, X., Wu, Y., & Wu, J. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.01.043 · Cited by 4
Liver regeneration: cytokine regulation targeting hepatocytes and beyond
Xiao, T., Jin, Z., Deng, J., & Meng, W. (2026) · Life Medicine · doi:10.1093/lifemedi/lnag004 · Cited by 4
“Finally, advanced delivery systems including ligands targeting HSCs are being developed to improve the specificity and efficacy of antifibrotic agents [189].”
Nanomedicine-Driven Modulation of Signaling Pathways in Hepatic Fibrosis
Ji, P., Li, Y., Jin, Y., Dong, Y., Li, L., Ma, Z., Liu, L., Zhang, Y., & Ren, Z. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s418132 · Cited by 4
“9 The development of liver fibrosis is closely associated with a series of complex signaling pathways and molecular targets.”
InfluentialLiver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions
Qu, J., Qin, W., Dong, M., Ma, Z., Li, S., Liu, R., Chen, R., Li, C. H., & Li, X. (2026) · MedComm · doi:10.1002/mco2.70750 · Cited by 4
“The activation of SMAD pathway also upregulated other profibrotic genes, including those encoding alpha-smooth muscle actin ( α -SMA) and connective tissue growth factor [ 24 ].”
Bortty, J. C., Chakraborty, G. S., Batra, S., Das, J., Polok, S. D., & Saha, P. (2025) · International Conference on Intelligent Computing and Control Systems (ICICCS) · doi:10.1109/iciccs65191.2025.10985713 · Cited by 3
“Liver is a vital organ essential for various critical functions that sustain life [1].”
GPR56 function as a key repressor in hepatocyte pyroptosis and the pathogenesis of liver fibrosis
Shi, Z., Liu, Q., Zhang, M., Du, X., He, Y., Zheng, L., Wei, H., Han, T., & Zhang, K. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06619-8 · Cited by 5
Redox Biology and Insulin-like Growth Factor-Binding Protein-6: A Potential Relationship
Coda, A. R. D., Liso, A., & Bellanti, F. (2025) · Biology · doi:10.3390/biology14070747 · Cited by 3
“In liver fibrosis, for instance, a disrupted redox environment supports the activation of profibrotic signaling pathways like TGF-β , which drives excessive ECM production [34].”
Targeting tumor vascular endothelial cells for hepatocellular carcinoma treatment
Zhang, C., & Yang, M. J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i29.110114 · Cited by 3
“The expression of platelet-derived growth factor produced by endothelial cells and macrophages can stimulate the activation of hepatic stellate cells by interacting with its receptor platelet-derived growth factor receptor to promote liver fibrosis[13].”
Hu, M., Li, J., Zhang, H., Ma, Y., Zhao, B., Xiao, L., Liang, W. Y., Wang, Y., Wang, C., Wu, C., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117907 · Cited by 2
The Role of HSP47 in Thrombotic Disorders: Molecular Mechanism and Therapeutic Potential
Teodoru, M., Stoia, O., Catană, M.-G., & Tonch-Cerbu, A.-K. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040283 · Cited by 3
“Abnormal HSP47 expression leads to pathological collagen synthesis and extracellular matrix (ECM) disruption associated with DVT pathogenesis [6,10].”
McCary, A. G., Sheu, Y.-S., Chesbrough, K., & Jonas, M. C. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.03.011 · Cited by 2
Wu, W., Liao, Y., Liang, J., Huang, M., Zhang, G., Hu, Y., Yuan, C., & Li, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-09002-1 · Cited by 2
Pan, M., Li, H. Z., Guo, H., Luo, S., Yao, J., Zhang, M., Luo, Y., & Shi, X. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120862 · Cited by 2
Xu, J., Sang, X., He, Y., Ke, J., Xu, J., Liu, T., Wang, J., Zhai, H., Chen, X., Shi, X., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1730255 · Cited by 3
Torres‐Oteros, D., Nicola‐Llorente, M., Sanz‐Lamora, H., Pérez‐Martí, A., Marrero, P. F., Canudas, S., Haro, D., & Relat, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010194 · Cited by 2
“Several terms also pointed to fibrogenesis-related processes, including muscle tissue development and components linked to myofibroblast activation (e.g., myofibril, muscle myosin complex, M band), which are commonly associated with the hepatic stellate cell activation [38,39].”
Neureiter, D., Kiesslich, T., & Ocker, M. (2026) · Medical Sciences · doi:10.3390/medsci14010110 · Cited by 3
“Several other factors also contribute to this complex and multi-layered signaling network that connects chronic liver disease and injury with inflammation and aberrant regeneration with fibrogenesis and ultimately hepatocarcinogenesis [82–84].”
Unlocking the potential of mRNA nanomedicines for comprehensive fibrosis therapy
Yang, Y., Li, C., Xiong, W., Li, C., & Xiao, J. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102917 · Cited by 2
“11,64 At the metabolic level, activated HSCs undergo profound metabolic reprogramming characterized by enhanced glycolysis, lipid accumulation, and persistent production of ROS.”
Wang, C., Jiang, T., Zheng, L., Zheng, Y., & Xie, X. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178830 · Cited by 3
Gut–liver axis molecular mechanisms in alcohol-associated liver disease
Jiang, Y., & Llorente, C. (2026) · Alcohol · doi:10.1016/j.alcohol.2026.04.001 · Cited by 2
Zhang, S., Zhang, X., Wang, M., Guo, L., & Tan, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145221 · Cited by 4
Integrated multi‑omics analysis of liver metabolic dysregulation in ACE2 knockout mice
Xiao, S., Guo, J., Yu, B., Zhao, S., Shang, Y., Li, N., Cui, J., Song, F., & Jiang, P. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5575 · Cited by 4
“Sustained inflammation activates HScs, inducing collagen deposition and fibrosis, with potential progression to cirrhosis (62).”
Badran, H. M., Elsabaawy, M., Magdy, M., Omar, H. M., Hendy, O. M., Awaad, E. K., Alkhalifa, M., & Abozeid, M. (2025) · BMC Gastroenterology · doi:10.1186/s12876-024-03542-y · Cited by 2
“Treatment options for the management of individuals with MAFLD can lead to resolution of hepatic fibrosis, during which hepatic stellate cells undergo apoptosis, become senescent, or revert to an inactive state with diminished PDGFRβ production [64].”
Almukadi, H. S., Alotaibi, N. N., Shaik, R. A., Abdel‐Naim, A. B., Esmat, A., & Eid, B. G. (2025) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_254_25 · Cited by 1
Chen, J., Tang, X., Fang, M., Hu, S., Wang, J., Chen, X., Xiao, Q., Wang, X., Xie, F., & Tan, S. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121865 · Cited by 1
Liu, C.-F., Pan, C.-M., & Lee, C.-L. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090697 · Cited by 1
“Hepatic fibrosis is characterized by repeated injury-repair cycles leading to activation of hepatic stellate cells (HSCs) and excessive accumulation of extracellular matrix (ECM) proteins such as type I/III collagen and fibronectin (Fn) [5].”
Chandane-Tak, M., Suneesh, N. S., Mukherjee, S., Khan, A. A., & Mukherjee, A. (2025) · Virology · doi:10.1016/j.virol.2025.110747 · Cited by 1
Gou, Y., Wang, T., Xu, L., Wang, F., Chen, S., & Yin, Z. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157611 · Cited by 3
Emerging importance of ALDH2 in liver diseases and its potential therapeutic role
Wang, S., Xu, S., Xia, G., Wang, X., & Lv, X. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117732 · Cited by 2
Sohn, E. J., & Oh, S.-O. (2026) · Analytical Cellular Pathology · doi:10.1155/ancp/2283163 · Cited by 1
Navigating thyroid hormone signaling in liver fibrosis: mechanisms and clinical implications
Ye, C., Xu, K., Lan, X., Quan, S., Li, Y., Yang, W., & liu, S. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02820-8 · Cited by 1
YANG, F., Chen, Y. F., Wang, Y., Zheng, G., Abouelnazar, F. A., Fan, L., Wang, Y., & Yan, Y. (2026) · Autophagy · doi:10.1080/15548627.2026.2642976 · Cited by 1
“The activation of hepatic stellate cells (HSCs) represents the central pathological event in liver fibrosis [15].”
Li, M., Hao, X., Li, Y., Zhang, C., Chen, Y., Yu, Z., Li, Q., Tan, L., Xiang, D., Shang, Q., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1765594 · Cited by 1
Li, Y., Wang, Q., Liao, Z., Wu, J., Yu, S., Yan, H., & Xie, Z. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04970-1 · Cited by 2
“First, considering the dual role of HSCs in driving fibrosis and promoting liver repair [69], our approach aims not to eradicate HSCs but to selectively target persistently activated HSCs, which exhibit metabolic reprogramming and drive pathological ECM deposition [70].”
Yang, A., Yan, X., Wang, Y., Han, Q., Tong, X., Chen, S., Zhao, X., Chen, W., Jia, J., Schuppan, D., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001715 · Cited by 2
“[11,12] The well-characterized activation-reversibility paradigm of HSCs—spanning activation, fibro-genesis, and potential apoptosis—provides a rational framework for developing HSC-targeted therapies.”
Hu, Y., Zhang, L., & Yin, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-43991-x · Cited by 1
Yong, J., Wang, H., Liu, L., Zhao, H., Sun, C. J., Wang, S., Luo, P., Xia, Y., & Ding, B. W. (2026) · Critical Public Health · doi:10.1080/09581596.2026.2664251 · Cited by 1
Yu, L., Zhang, L., Gao, L., Huang, S., Qin, X., Wang, Z., Li, S., Mei, C., Zhang, M., Zhang, Y., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115100 · Cited by 1
Unifying and unique roles of non-coding RNA biomarkers in liver and heart fibrosis
Boichenko, V., Frolova, S., Voellenkle, C., Zaccagnini, G., Ferrero, P., Bassareo, P. P., Luciani, G. B., Gorelik, J., & Martelli, F. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119607 · Cited by 2
“HSC are central players of fibrogenesis: while quiescent in a healthy liver, they differentiate into myofibroblast-like cells upon injury, acquiring the capacity to secrete ECM components, and drive scar formation [20].”
Extracellular matrix stiffness in chronic liver disease: From mechanisms to treatments
Xi, Z.-H., Sun, W.-J., Li, M., Dong, Q.-Q., Dong, X., Qiao, Z.-L., Tao, H., Yang, J., & Lu, C. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118194 · Cited by 1
Erianin ameliorates liver fibrosis through the PRDX3/NLRX1 axis
Zhu, M., Yang, X., Xie, J., Shi, X., Li, J., Shi, Y., Zhang, L., Tian, X., Li, Y., Yao, J., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179110 · Cited by 1
Andrés‐Rozas, M., Aristu-Zabalza, P., Chullo, G., Liu, G., Fundora, Y., Villa, R., Lopez, J., Folguera, C., Fernández‐Iglesias, A., Guixé‐Muntet, S., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119711 · Cited by 1
Zhang, Z., Sun, M., Yang, Y., Xie, J., Li, Y., Lin, Y., Liu, Y., Liao, Y., & Lin, L. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158631 · Cited by 2
Hajiasgharzadeh, K., Pashazadeh, F., Alipour, M. R., Rahbarghazi, R., Shoaran, M., & Ahmadi, M. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103909 · Cited by 1
Ali, L. S., Mohamed, G. A., El‐Mansy, A. A., El-Bayoumi, K. S., Sobhey, M. Y., El-Beltagy, A. E.-F. B. M., & Ghanem, R. A. (2025) · Arab Journal of Basic and Applied Sciences · doi:10.1080/25765299.2025.2516880 · Cited by 1
“…abema-ciclib induces liver fibrosis may be ascribed to its probable involvement in hepatocyte apoptosis, persistent inflammation accompanied by cytokine release, stimulation of hepatic stellate cells (HSCs), and disruption of the epithelial or endothelial barrier (Akkız, Gieseler, & Canbay, 2024).”
Yuan, X., Zhang, K., Wang, D., Li, J., Lyu, P., Zhao, X., Zhang, K., Li, H., Liu, B., & Ma, L. (2025) · Liver International · doi:10.1111/liv.70302 · Cited by 2
Ferret-Miñana, A., Alcaraz, E., Horrillo, R., Ramón-Azcón, J., & De Chiara, F. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1798323
Metadata
- Authors
- Akkız, H., Gieseler, R. K., & Canbay, A.
- Affiliations
- Bahçeşehir University (TR)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Corresponding author
- Akkız, Hikmet
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-07-18
- Volume
- 25
- Issue
- 14
- Pages
- 7873
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11277292
- OpenAlex
- W4400775597
- Semantic Scholar
- 8810ad06f0650b984f245dec696c68e2f2723093
- Cited by
- 191
- References
- 223
- Citations by year
- 2026: 112 · 2025: 70 · 2024: 9
- FWCI
- 13.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, hepatic stellate cells, hepatic fibrogenesis, myofibroblast transdifferentiation, extracellular matrix deposition, hepatic stellate cell activation, HSC heterogeneity, macrophages, hepatocyte death, liver inflammation, antifibrotic therapy, cirrhosis reversal, cellular stress response, cytokines and chemokines
- MeSH terms
- Animals, Humans, Liver Cirrhosis, Hepatic Stellate Cells, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.